Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?  by Ringdén, Olle et al.
W
S
-
I
b
h
i
o
m
n
p
d
i
M
a
t
e
a
Biology of Blood and Marrow Transplantation 10:128-134 (2004)
 2004 American Society for Blood and Marrow Transplantation
1083-8791/04/1002-0005$30.00/0
doi:10.1016/j.bbmt.2003.10.001
1hich Donor Should Be Chosen for Hematopoietic
tem Cell Transplantation among Unrelated HLA-A,
B, and -DRB1 Genomically Identical Volunteers?
Olle Ringde´n,1,2 Marie Schaffer,2 Katarina Le Blanc,1,2 Ulla Persson,2 Dan Hauzenberger,2
Mohammad R. Abedi,2 Olle Olerup,2 Per Ljungman,3 Mats Remberger1,2
1Centre for Allogeneic Stem Cell Transplantation; 2Division of Clinical Immunology; and 3Department of
Hematology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
Correspondence and reprint requests: Olle Ringde´n, MD, PhD, Division of Clinical Immunology, Huddinge
University Hospital, F79, SE-141 86 Stockholm, Sweden (e-mail: Olle.Ringden@labmed.ki.se).
Received July 2, 2003; accepted September 24, 2003
ABSTRACT
The aim of this study was to identify significant prognostic factors by using unrelated genomically HLA-A, -B
and -DRB1–identical donors. Such data could help to choose the best donor. We studied 136 consecutive
patients with hematologic malignancies and a median age of 32 years (range, 0-55 years) who received
hematopoietic stem cell transplantation. Bone marrow grafts were given to 83 and peripheral blood stem cells
to 53 patients. The cumulative incidence of grade II to IV acute graft-versus-host disease (GVHD) was 30%
and of chronic GVHD was 54%. At 5 years, the overall transplant-related mortality (TRM) was 34%, and
patient survival was 50%. In Cox multivariate analysis, 32 potential risk factors were analyzed. Monoclonal
antibody OKT-3 during conditioning was correlated with grade II to IV acute GVHD, chronic GVHD, and
TRM. HLA-DP mismatch was associated with poor TRM and poor survival. Cytomegalovirus-seropositive
patients with a seronegative donor had a decreased leukemia-free survival. Five-year TRM was 14% with no
risk factor, 38% with 1 risk factor, and 87% with 2 risk factors. The 5-year survival was 72%, 48%, and 30%
with 0, 1, and 2 risk factors, respectively. We concluded that unrelated hematopoietic stem cell transplantation
may be improved if an optimal donor and immunosuppression are chosen.
© 2004 American Society for Blood and Marrow Transplantation
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eNTRODUCTION
Only one third of the patients who may be cured
y hematopoietic stem cell transplantation (HSCT)
ave an HLA-identical sibling. Therefore, large reg-
stries with volunteer donors have been established all
ver the world. Worldwide, there are now registries in
ost countries that perform HSCT. Unrelated do-
ors are increasingly used [1-9]. For instance, in our
rogram, 70% of the transplants were from unrelated
onors during 2002. HLA-A, -B, and -DRB1 identity
s of the utmost importance for outcome [10-15].
olecular typing for HLA class I and II alleles can
llow more accurate donor-recipient matching and
hereby improve clinical outcome after HSCT. How-
ver, with the increasing number of volunteer donors
vailable, it may be possible to choose between several p
28atched donors. Other factors have also been re-
orted to be of importance for outcome after HSCT
ith unrelated donors: these include cytomegalovirus
CMV)-seropositive status in the donor if the recipi-
nt is CMV seropositive, bone marrow cell dose, do-
or age, and the use of anti–T-cell globulin (ATG)
uring conditioning [3,16-20]. With genomically
ell-matched unrelated donors, prognostic factors
igniﬁcant for the outcome of transplantation with
LA-identical siblings—such as female donor to male
ecipient, herpesvirus immunity in recipients and do-
ors, body mass index, and posttransplantation treat-
ent with granulocyte colony-stimulating factor (G-
SF)—may be of importance for outcome [21-25]. To
lucidate these points, this risk factor analysis was
erformed that included only recipients of HSCT
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Which Unrelated Donor Should Be Chosen for HSCT?
Brom unrelated donors who were genomically HLA-A,
B, and -DRB1 identical.
ATERIALS AND METHODS
atients and Donors
Among 291 consecutive recipients of unrelated
onor transplants, 211 were genomically typed for
LA class I and II, 18 had an HLA-A, -B, or -DRB1
ismatch, and 29 had a subtype mismatch. The study
opulation therefore consisted of 164 recipients of
LA-A, -B, and -DRB1 genomically unrelated
atched donors. Among those, 136 had hematologic
alignancies.
Transplantations were performed between 1991
nd 2003. Patient and donor characteristics are shown
n Table 1. All patients and donors were retrospec-
ively HLA class I and class II typed by allele-level
olymerase chain reaction ampliﬁcation with se-
uence-speciﬁc primers [26,27]. In cases in which typ-
ng allowed the deﬁnition of more than 1 allele, it was
ssumed to be the allele usually seen in white individ-
als. All donor-recipients were DRB5 identical. The
ource of stem cells was bone marrow in 83 cases and
-CSF–mobilized peripheral blood stem cells (PBSC)
n 53 cases [28].
onditioning and Supportive Care
Most patients received total body irradiation
TBI): 54 (40%) of 136 received 10 Gy (lungs were
able 1. Patient and Donor Characteristics (n  136)
Characteristic Data
ecipient age, y (range) 32 (0-55)
ecipient sex (female/male) 62/74
onor age, y (range) 37 (19-56)
onor sex (female/male) 57/77
isease
Acute myeloid leukemia 41 (30%)
Acute lymphoid leukemia 31 (23%)
Chronic myeloid leukemia 49 (36%)
Myelodysplastic syndrome 9 (7%)
Lymphoma 3 (2%)
Myeloma 1
Myeloproliferative disorder 1
Chronic lymphoid leukemia 1
isease status
First complete remission/chronic phase 68 (54%)
Second or third remission/chronic phase 40 (32%)
Partial remission 6 (5%)
Not in remission/chronic phase 11 (9%)
ucleated cell dose ( 108/kg) (range) 3.6 (0.6-63.8)
D34 cell dose ( 106/kg) (range) 5.8 (0.41-56.4)
BO compatibility
Identity 56 (41%)
Minor incompatibility 40 (29%)
Major incompatibility 40 (29%)hielded so that the patient received a median of 9 [
B&MTy), and 38 (28%) received 12 Gy of fractionated TBI
3 Gy on 4 consecutive days). TBI was combined with
yclophosphamide 60 mg/kg for 2 consecutive days
29]. Busulfan 4 mg/kg on 4 consecutive days was
ombined with cyclophosphamide 60 mg/kg for 2
onsecutive days in patients with hematologic malig-
ancies (n  44) [30]. All but 1 patient received ATG
to 5 mg/kg/d (n  108) or muromone ab-CD3
OKT-3; 5 mg/d) for 2 to 5 days (n  27) before
ransplantation [31]. Methotrexate (MTX) 8 to 12 mg
r cytarabine 20 mg was given intrathecally twice
efore HSCT to prevent central nervous system
CNS) leukemia in patients with acute lymphoid leu-
emia, acute myeloid leukemia FAB M4 or M5, or a
istory of CNS disease. Patients with previous CNS
isease were given intrathecal treatment until 24
onths after HSCT. Between 1995 and 2000, G-CSF
as given to 100 patients (74%) from day 10 until
eutrophil engraftment 0.5  109/L for 2 days.
raft-versus-Host Disease Prophylaxis
The vast majority of patients (128/136; 94%) re-
eived cyclosporine (CsA) combined with 4 doses of
TX [29,32]. Intravenous CsA was started on day
1; the dose ranged from 5 to 10 mg/kg/d, with the
igher dose given to small children. On the day of
SCT, CsA was decreased to 3 to 7.5 mg/kg/d. On
ay 1, or as soon as the patient could take CsA
rally, 12.5 mg/kg/d was given in 2 doses to adults,
nd a higher dose, 12.5 to 20 mg/kg/d, was given to
hildren. During the ﬁrst month, blood CsA trough
evels were kept at approximately 200 to 300 ng/mL.
sA was discontinued after 6 months if possible. Six
atients received CsA combined with prednisolone be-
ause they did not tolerateMTX, and 2 patients received
sA combined with mycophenolate mofetil [33].
iagnosis and Treatment of Graft-versus-Host
isease
Both acute and chronic graft-versus-host disease
GVHD) were diagnosed on the basis of clinical
ymptoms or biopsy samples from skin, liver, gastro-
ntestinal tract, or oral mucosa [34]. Patients were
reated for grade I acute GVHD with prednisolone
tarting at 2 mg/kg/d, which was tapered after the
nitial response [35]. In more severe cases, methyl-
rednisolone, ATG, MTX, and/or psoralen and ultra-
iolet A (PUVA) or extracorporeal PUVA were given.
everal strategies were used to treat extensive chronic
VHD, including prednisolone, CsA, and prednisone
n alternate days [36], PUVA or extracorporeal
UVA, thalidomide, or total lymph node irradiation
34].
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1tatistics
Time to acute GVHD, chronic GVHD, trans-
lant-related mortality (TRM), survival, and re-
apse-free survival were determined with the life-
able method by using the log-rank (Mantel-
aenzel) test, taking sensored data into account
37]. The logistic regression model was used to
nalyze risk factors for acute GVHD. The Cox
egression model was used for univariate and mul-
ivariate analysis for chronic GVHD, TRM, sur-
ival, and relapse-free survival [38]. Thirty potential
isk factors for outcome were studied (Table 2).
nly factors at 10% levels in the univariate anal-
sis were introduced into the stepwise elimination
ultivariate analysis. This was done to reduce the
umber of competing factors in the multivariate
nalysis (Table 3). When multiple comparisons are
able 2. Univariate Analysis of Risk Factors for Transplant-Related M
Factor 0/1 n
ex M/F 74/62
MI Continuous
ge Continuous
TX No/yes 8/128
tage Early/late 70/66
CT year Continuous
C dose Continuous
D34 dose <4.0/>4.0 26/51
BO MM No/yes 56/80
BO minor MM No/yes 96/40
BO major MM No/yes 96/40
onor sex M/F 77/57
onor age <30/>30 35/95
KT-3 No/yes 109/27
plenectomy No/yes 131/5
to M No/yes 113/21
mm F to M No/yes 123/11
BSC BM/PBSC 83/53
-CSF No/yes 36/100
ec virus 0-2/3-4 25/106
on virus 0-2/3-4 25/85
MV / No/yes 75/48
MV / No/yes 109/14
MV / No/yes 87/36
MV / No/yes 98/25
LA C Match/MM 92/44
LA DRB3 Match/MM 117/9
LA DRB4 Match/MM 111/5
LA DPAB 0/1/2 20/62/47
LA DQA 0/1/2 114/12/7
ML No/yes 95/41
ML No/yes 87/49
indicates female; M, male; BMI, body mass index; MTX, methot
these stages; SCT, stem cell transplantation; NC dose, nucleate
peripheral blood stem cells; Rec virus, recipient virus seropositiv
virus, or cytomegalovirus; CMV /, seropositive donor/recip
mismatch; OR, odds ratio; AML, acute myeloid leukemia; CML
Included in multivariate analysis.erformed, there is always a risk of statistical sig- a
30iﬁcance by chance. A female donor was considered
s immunized if she had been pregnant or received
blood transfusion. Patients in ﬁrst complete re-
ission or ﬁrst chronic phase were considered as
aving low-risk disease. All others were considered
s having high-risk disease. An ABO minor mis-
atch was a donor who had ABO antibodies against
he patients’ erythrocytes, whereas an ABO major
ismatch was a patient who had ABO antibodies
gainst donor erythrocytes. The cumulative proba-
ility curves for GVHD, TRM, and survival were
alculated with the Kaplan-Meier method. Sensored
bservations were taken into account. Most of these
actors are well known and have been studied pre-
iously. If a Bonferroni correction was performed
or the 8 to 10 new factors introduced in this study,
nly factors signiﬁcant at .005 had to be considered
(TRM) and Survival
TRM Survival
OR P Value OR P Value
1.31 .40 0.93 .78
1.00 .95 1.00 .92
1.00 .99 1.00 .68
0.49 .17 0.61 .29
1.28 .42 1.65 .05†
0.93 .18 0.97 .57
0.99 .94 1.01 .52
1.92 .20 1.46 .32
1.12 .73 1.20 .49
1.13 .73 1.31 .32
1.01 .98 0.93 .80
1.21 .55 1.15 .60
0.91 .80 0.81 .45
2.29 .01† 1.54 .13
1.48 .60 1.58 .44
1.73 .15 1.63 .13
1.92 .18 1.55 .30
1.11 .76 1.10 .72
0.77 .47 1.04 .89
0.92 .83 1.03 .93
0.76 .49 1.13 .74
0.83 .56 0.69 .20
2.10 .08† 1.79 .13
0.99 .97 1.15 .64
0.79 .58 0.99 .98
0.78 .47 0.66 .16
1.65 .35 1.20 .72
1.72 .46 2.61 .06†
1.86 .02† 1.82 .005†
1.14 .66 1.00 .99
1.32 .40 1.68 .05†
0.73 .33 0.50 .016†
disease stage: early, ﬁrst remission or chronic phase; late, beyond
ose; Imm F, immunized female donor; BM, bone marrow; PBSC,
2 or 3-4 of herpes simplex virus, varicella zoster virus, Epstein-Barr
1/2, no, 1, or 2-locus mismatch for HLA DP and HLA DQ; mm,
nic myeloid leukemia.ortality
rexate;
d cell d
e for 0-
ient; 0/
, chros statistically signiﬁcant.
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BESULTS
isk Factors for Acute and Chronic GVHD
The cumulative incidence of grade II to IV acute
VHD was 30%. In logistic regression multivariate
nalysis, 2 factors were signiﬁcant for grade II to IV
cute GVHD: treatment with OKT-3 and PBSC
rafts (Table 3). However, if the Bonferroni correc-
ion was considered, PBSC grafts did not reach sig-
iﬁcance. Patients who received OKT-3 during con-
itioning had an increased risk (55%) of developing
rade II to IV acute GVHD, compared with 24% in
hose treated with ATG (P  .001). Recipients of
BSC grafts had a probability of grade II to IV acute
VHD of 41%, compared with 23% in those who
eceived bone marrow grafts (P  .03). The risk of
rade II to IV acute GVHD increased signiﬁcantly
ith more risk factors (Figure 1). If no risk factor was
resent, the probability of grade II to IV acute GVHD
as 15%, versus 41% with 1 risk factor and 71% with
risk factors.
The cumulative incidence of chronic GVHD was
4%. In the multivariate analysis, OKT-3 treatment
as signiﬁcant for chronic GVHD (Table 3).
isk Factors for TRM
In Cox regression univariate analysis, 2 factors
able 3. Multivariate Analysis for Risk Factors for Acute and Chronic
VHD, Transplant-Related Mortality (TRM), Survival, and
eukemia-Free Survival (LFS)
Factor OR 95% CI
P
Value
After
Bonferroni
Correction
isk factors for acute GVHD
OKT-3 4.97 1.88-13.1 .001
PBSC 2.98 1.27-7.00 .01 .07
isk factors for chronic GVHD HR
OKT-3 3.06 1.61-5.85 <.001
Recent transplantation year 0.87 0.78-0.97 .016 .10
isk factors for TRM HR
OKT-3 3.21 1.55-6.62 .002
DP mismatch 2.10 1.21-3.63 .008
CMV / 3.05 1.19-7.82 .02 .14
isk factors for survival HR
CML 0.32 0.16-0.67 .002
DP mismatch 1.84 1.22-2.78 .004
Recent transplantation year 0.84 0.74-0.97 .01 .07
isk factors for LFS HR
CMV-seronegative donor
and seropositive recipient 3.10 1.50-6.39 .002
DP mismatch 1.55 1.05-2.30 .026 .18
CML 0.43 0.22-0.84 .014 .10
Recent transplantation year 0.86 0.75-0.98 .028 .20
R indicates odds ratio; CI, conﬁdence interval; HR, hazards ratio;
OKT 3, muromone antibody against CD3 during conditioning;
PBSC, peripheral blood stem cells; CML, chronic myeloid leu-
kemia.ere signiﬁcant at the 5% level and 1 additional factor a
B&MTas signiﬁcant at the at the 5% to 10% level; these
ere included in the subsequent stepwise elimination
ultivariate analysis (Table 2). OKT-3 treatment,
LA-DP mismatch, and a CMV-seronegative donor
o a CMV-seropositive patient (not signiﬁcant with
onferroni correction) were associated with TRM.
ith no risk factor, TRM was 14%, compared with
8% with 1 risk factor and 87% with 2 risk factors
Figure 2). No patient had all 3 risk factors.
isk Factors Associated with Poor Survival
In univariate analysis for patient survival, 4 factors
ere signiﬁcant at the 5% level (Table 2). Three
actors were signiﬁcant in the multivariate analysis:
LA-DP mismatch (P  .002), chronic myeloid leu-
emia (CML; P  .002), and transplantation year (not
igniﬁcant with the Bonferroni correction; Table 3).
ive-year patient survival was 73% in HLA-DP
atches, compared with 57% in HLA-DP 1-antigen
igure 1. The cumulative probability of grade II to IV acute
VHD in patients with 0 to 2 signiﬁcant risk factors (RF) present
ccording to Table 3.
igure 2. The cumulative probability of transplant-related mortal-
ty in patients with 0 to 2 signiﬁcant risk factors (RF) present
ccording to Table 3.
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1ismatches and 34% in 2-antigen mismatches (P 
016). Five-year survival was 63% with CML versus
1% in the other disorders (P  .01). In those with 0
r 1 risk factors, the 5-year probability of survival was
2%, compared with 48% with 1 risk factor and 30%
ith 2 risk factors (Figure 3). This outcome may not
eem compatible with the risk factor analysis for TRM
Figure 2). However, only risk factors signiﬁcant in
ultivariate analysis were included. Therefore, differ-
nt risk factors were included in the risk factor analysis
f TRM and survival.
isk Factors for Leukemia-Free Survival
In multivariate analysis, poor leukemia-free sur-
ival (LFS) was associated with CMV-seronegative
rafts to CMV-seropositive recipients (Table 3). Di-
gnosis other than CML, HLA-DP mismatch, and
arly transplantation year were signiﬁcant in the mul-
ivariate analysis for LFS, but not after the Bonferroni
orrection.
ISCUSSION
GVHD is a major reason for morbidity and mor-
ality after HSCT, especially with unrelated donors
1-9]. In this study, treatment with OKT-3 during
onditioning and PBSC grafting had an increased risk
f acute GVHD (Table 3). We previously reported
hat OKT-3, compared with ATG, increased the risk
f acute GVHD grade II to IV with unrelated donors
31]. A reason for this may be that OKT-3 triggers
ytokine release, such as tumor necrosis factor-, in-
erferon-, and interleukin-2, which may activate
cute GVHD [39-41]. We used OKT-3 during 1
eriod because it was cheaper than ATG. However, in
ore recent years, we have exclusively used ATG.
The use of PBSC grafts also resulted in an in-
reased risk of acute GVHD, which is in contrast to a
igure 3. Probability of survival in patients with 0 to 2 signiﬁcant
isk factors (RF) present according to Table 3.revious study that found a similar incidence of acute i
32VHD with PBSC or bone marrow from unrelated
onors [28]. Furthermore, studies including several
housand patients undergoing HSCT with HLA-
dentical sibling donors showed no difference with
egard to acute GVHD with use of PBSC compared
ith bone marrow [42]. Therefore, this ﬁnding has to
e taken with caution. Furthermore, there was only a
rend when the Bonferroni correction was included
P  .07; Table 3).
Risk factors for chronic GVHD included treat-
ent with OKT-3 and an early transplantation year.
robably immunosuppression has improved in more
ecent years, although time was not signiﬁcant after
he Bonferroni correction (Table 3). PBSC were not
ssociated with an increased risk of chronic GVHD, in
ontrast to the experience in HLA-identical siblings
42,43]. The reason for this may be the overall high
isk for chronic GVHD with unrelated donors. This is
n keeping with a previous report with unrelated do-
ors [28].
GVHD, infections, and toxicity are the main
auses of TRM after HSCT [44]. Therefore, the risk
actors signiﬁcant for acute and chronic GVHD may
e the same for TRM. Indeed, OKT-3 treatment
as signiﬁcantly associated with GVHD and TRM
Table 3).
In these recipients of genomically typed HLA-A,
B, and -DRB1–identical unrelated grafts, HLA-DP
ismatch was a signiﬁcant factor associated with
RM, low survival, and LFS (Table 3). The role of
P mismatch is in agreement with previous studies
27,44-46]. In our study, DP mismatch included
PA1 and DPB1 mismatches. That DP acts as an
mportant transplantation antigen was previously sug-
ested [47]. Signiﬁcant proliferation was induced in
ixed lymphocyte cultures between HLA-A, -B, -DR,
nd -DQ–compatible individuals who were HLA-DP
ncompatible. The role of DQA1 could not be evalu-
ted, because most donor-recipient pairs were identi-
al. Our study is not comparable with most other
eports of unrelated HSCT, because those also in-
luded patients who received major HLA–mismatched
ransplants [12-15,44]. Furthermore, in our study, we
lso analyzed other risk factors of importance for out-
ome after allogeneic stem cell transplantation.
In addition to DP mismatch, CMV-seropositive
ecipients of grafts from CMV-seronegative donors
ad a decreased LFS (Table 3). A previous study from
he European Group for Blood and Marrow Trans-
lantation also reported a favorable outcome in CMV-
eropositive recipients if the donor was also CMV
eropositive compared with CMV seronegative [16].
e did not see any signiﬁcant role of donor age or cell
ose, which were shown to be important for outcome
fter transplantation with unrelated donors [17,18].
he reason for the differences in ﬁndings may be that
n our study, we included only patients with well-
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Beﬁned genomic tissue typing for donors and recipi-
nts. The other studies included patients and donors
ho were matched for HLA class I by serologic typ-
ng. In addition, 2 of the studies were multicenter
egistry studies, which by nature include a much more
eterogenic cell population [15,17]. All our patients
ere given ATG or OKT-3. Therefore, the incidence
f acute GVHD was lower than in other studies [20].
urthermore, some of the other studies included more
atients, and it is possible that to detect differences
egarding the role of donor age and cell dose, many
ore patients are required than were included in this
nalysis. Therefore, for the single patient, these fac-
ors are probably less important than, for instance, DP
atching. Risk factors for outcome found to be of
mportance in HLA-identical siblings, such as herpes-
irus immunity in recipients and donors, body mass
ndex, and posttransplantation treatment with G-CSF,
eem to be less important with unrelated donors, as
as found in this study [22-25]. The risk factors that
ecame nonsigniﬁcant with the Bonferroni correction
ay have been signiﬁcant by chance in the Cox mul-
ivariate analysis (Table 3).
To conclude, using unrelated donors who are
enomically HLA-A, -B, and -DRB1 identical, DP
atch was important for survival and LFS. It was also
mportant to choose ATG rather than OKT-3 as
mmunosuppression during conditioning. Further-
ore, in CMV-seropositive recipients, CMV-sero-
ositive donors, if available, should be selected.
CKNOWLEDGMENTS
We thank the staff at Centre for Allogeneic Stem
ell Transplantation, Departments of Hematology
nd Pediatrics, for competent and compassionate care
f the patients. We thank Inger Hammarberg for
reparation of this manuscript. This study was sup-
orted by grants from the Swedish Cancer Society
0070-B02-16XAC), the Children’s Cancer Founda-
ion (2000/067 and 2002/074), the Swedish Research
ouncil (K2003-32X-05971-23A), the Cancer Society
n Stockholm (02:181), the Tobias Foundation, and
he Karolinska Institutet.
EFERENCES
1. Beatty PG, Hansen JA, Longton GM, et al. Marrow transplan-
tation from HLA-matched unrelated donors for treatment of
hematologic malignancies. Transplantation. 1991;51:443-447.
2. Hows JM, Bradley BA, Gore S, Downie T, Howard M, Gluck-
man E. Prospective evaluation of unrelated donor bone marrow
transplantation. The International Marrow Unrelated Search
and Transplant (IMUST) Study. Bone Marrow Transplant. 1993;
12:371-380.
3. MacKinnon S, Hows J, Goldman JM, et al. Bone marrow
transplantation for chronic myeloid leukemia: the use of histo-
B&MTcompatible unrelated volunteer donors. Exp Hematol. 1990;18:
421-425.
4. Anasetti C, Howe C, Petersdorf EW, Martin PJ, Hansen JA.
Marrow transplants from HLA matched unrelated donors: an
NMDP update and the Seattle experience. Bone Marrow Trans-
plant. 1994;13:693-695.
5. Davies SM, Shu XO, Blazar BR, et al. Unrelated donor bone
marrow transplantation: inﬂuence of HLA A and B incompat-
ibility and outcome. Blood. 1995;86:1636-1642.
6. Ringde´n O. Bone marrow transplantation using unrelated do-
nors for haematological malignancies. Med Oncol. 1997;14:11-
22.
7. Hansen JA, Petersdorf E, Martin PJ, Anasetti C. Hematopoietic
stem cell transplants from unrelated donors. Immunol Rev.
1997;157:141-151.
8. Byrne JL, Stainer C, Cull G, et al. The effect of the serotherapy
regimen used and the marrow cell dose received on rejection,
graft-versus-host disease and outcome following unrelated do-
nor bone marrow transplantation for leukemia. Bone Marrow
Transplant. 2000;25:411-417.
9. Anasetti C, Petersdorf EW, Martin PJ, et al. Improving avail-
ability and safety of unrelated donor transplants. Curr Opin
Oncol. 2000;12:121-126.
0. Petersdorf EW, Anasetti C, Martin PJ, et al. Tissue typing in
support of unrelated hematopoietic cell transplantation. Tissue
Antigens. 2003;61:1-11.
1. Petersdorf EW, Longton GM, Anasetti C, et al. The signiﬁ-
cance of HLA-DRB1 matching on clinical outcome after
HLA-A, -B, -DR identical unrelated donor marrow transplan-
tation. Blood. 1995;86:1606-1613.
2. Nademanee A, Schmidt GM, Parker P, et al. The outcome of
matched unrelated donor bone marrow transplantation in pa-
tients with hematologic malignancies using molecular typing
for donor selection and graft-versus-host disease prophylaxis
regimen of cyclosporine, methotrexate and prednisone. Blood.
1995;86:1228-1234.
3. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimize out-
come after unrelated marrow transplantation by comprehensive
matching of HLA class I and II alleles in the donor and recip-
ient. Blood. 1998;92:3515-3520.
4. Speiser D, Tiercy J-M, Rufer N, et al. High resolution HLA
matching associated with decreased mortality after unrelated
bone marrow transplantation. Blood. 1996;87:4455-4462.
5. Morishima Y, Sasazuki T, Inoko H, et al. The clinical signiﬁ-
cance of human leukocyte antigen (HLA) allele compatibility in
patients receiving a marrow transplant from serologically
HLA-A, HLA-B and HLA-DR matched unrelated donors.
Blood. 2002;99:4200-4206.
6. Ljungman P, Brand R, Einsele H, et al. Donor CMV serolog-
ical status and outcome of CMV seropositive recipients after
unrelated donor stem cell transplantation; an EBMT Megaﬁle
analysis. Blood. In press.
7. Kollman C, Howe CWS, Anasetti C, et al. Donor characteris-
tics as risk factors in recipients after transplantation of bone
marrow from unrelated donors: the effect of donor age. Blood.
2001;98:2043-2051.
8. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow
cells from unrelated donors for treatment of high-risk acute
leukemia: the effect of leukemic burden, donor HLA-matching,
and marrow cell dose. Blood. 1997;89:4226-4235.
9. Ringde´n O, Remberger M, Carlens S, et al. Low incidence of
acute graft-versus-host disease, using unrelated HLA-A, -B and
133
22
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
O. Ringde´n et al.
1-DR compatible donors and conditioning including anti-T-cell
antibodies. Transplantation. 1998;66:620-625.
0. Remberger M, Storer B, Ringde´n O, Anasetti C. Association
between pretransplant thymoglobulin and reduced non-relapse
mortality rate after marrow transplantation from unrelated do-
nors. Bone Marrow Transplant. 2002;29:391-397.
1. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for
acute graft-versus-host disease. Br J Haematol. 1987;67:397-
406.
2. Bostro¨m L, Ringde´n O, Gratama JW, et al. A role of herpes
simplex virus serology for the development of acute graft-
versus-host disease. Bone Marrow Transplant. 1990;5:321-326.
3. Deeg HJ, Seidel K, Bruemmer B, Pepe MS, Appelbaum FR.
Impact of patient weight on non-relapse mortality after marrow
transplantation. Bone Marrow Transplant. 1995;15:461-468.
4. Le Blanc K, Ringde´n O, Remberger M. A low body mass index
is correlated to poor survival after allogeneic stem cell trans-
plantation. Haematologica. 2003;88:1044–1052.
5. Remberger M, Naseh N, Aschan J, et al. G-CSF given after
haematopoietic stem cell transplantation using HLA-identical
sibling donors is associated to a higher incidence of acute
GVHD II-IV. Bone Marrow Transplant. 2003;32:217-223.
6. Olerup O, Zetterquist H. HLA-DR typing by PCR ampliﬁca-
tion with sequence-speciﬁc primers (PCR-SSP) in 2 hours: an
alternative to serological DR typing in clinical practice includ-
ing donor-recipient matching in cadaveric transplantation. Tis-
sue Antigens. 1992;39:225-235.
7. Schaffer M, Aldener-Cannava´ A, Remberger M, Ringde´n O,
Olerup O. Role of HLA-B, HLA-C and HLA-DPA1 incom-
patibilities in the outcome of unrelated stem-cell transplanta-
tion. Tissue Antigens. 2003;61:1-8.
8. Ringde´n O, Remberger M, Runde V, et al. Peripheral blood
stem cell (PBSC) transplantation from unrelated donors: a
comparison with marrow transplantation. Blood. 1999;94:455-
464.
9. Ringde´n O, Remberger M, Persson U, et al. Similar incidence
of graft-versus-host disease using HLA-A, -B and -DR identical
unrelated bone marrow donors as with HLA-identical siblings.
Bone Marrow Transplant. 1995;15:619-625.
0. Ringde´n O, Ruutu T, Remberger M, et al. A randomized trial
comparing busulphan with total body irradiation as condition-
ing in allogeneic marrow transplant recipients with leukemia: a
report from the Nordic Bone Marrow Transplantation Group.
Blood. 1994;83:2723-2730.
1. Remberger M, Svahn B-M, Hentschke P, Lo¨fgren C, Ringde´n
O. Effect on cytokine release and graft-versus-host disease of
different anti-T-cell antibodies during conditioning for unre-
lated haematopoietic stem cell transplantation. Bone Marrow
Transplant. 1999;24:823-830.
2. Storb R, Deeg HJ, Whitehead J, et al. Marrow transplantation
for leukemia and aplastic anemia: two controlled trials of a
combination of methotrexate and cyclosporine v cyclosporine
alone or methotrexate alone for prophylaxis of acute graft-v-
host disease. Transplant Proc. 1987;19:2608-2613.
3. McSweeney P, Storb R. Mixed chimerism: preclinical studies
and clinical applications. Biol Blood Marrow Transplant. 1999;5:
192-203.344. Ringde´n O, Deeg HJ. Clinical spectrum of graft-versus-host
disease, In: Ferrara JLM, Deeg HJ, Burakoff S. eds. Graft vs
Host Disease. Second Edition. New York: Marcel Dekker, Inc.;
1996, 525-559
5. Ringde´n O, Båryd I, Gahrton G, et al. Early treatment and
prophylaxis of graft-versus-host disease using prednisolone. In:
Bone Marrow Transplantation in Europe: Touraine JL, ed.
Excerpta Medica. Symposium Proceedings. Vol 2. Amsterdam:
Excerpta Medica; 1981:171-177.
6. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day
cyclosporine and prednisone for treatment of high-risk chronic
graft-versus-host disease. Blood. 1998;72:555-561.
7. Peto R, Pike MC, Armitage P, et al. Design and analysis of
randomized clinical trials requiring prolonged observation of
each patient. II. Analysis and examples. Br J Cancer. 1977;35:
1-39.
8. Cox DR. Regression models and life tables. J R Stat Soc B.
1972;34:187-220.
9. Holler E, Kolb HJ, Mo¨ller A, et al. Increased serum levels of
tumor necrosis factor alpha precede major complications of
bone marrow transplantation. Blood. 1990;75:1011-1016.
0. Antin J, Ferrara J. Cytokine dysregulation and acute graft-
versus-host disease. Blood. 1992;80:2964-2968.
1. Remberger M, Ringde´n O, Markling L. TNF alpha levels are
increased during bone marrow transplantation conditioning in
patients who develop acute GVHD. Bone Marrow Transplant.
1995;15:99-104.
2. Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral
blood stem cell transplantation may be associated with a high
risk of chronic graft-versus-host disease. Blood. 1997;90:4705-
4709.
3. Ringde´n O, Labopin M, Bacigalupo A, et al. Transplantation of
peripheral blood stem cells as compared with bone marrow
from HLA-identical siblings in adult patients with acute my-
eloid leukemia and acute lymphoblastic leukemia. J Clin Oncol.
2002;20:4655-4664.
4. Ringde´n O, Deeg HJ. Clinical spectrum of graft-versus-host
disease. In: Ferrara JLM, Deeg HJ, Burakoff S., eds. Graft vs
Host Disease. Second Edition. New York: Marcel Dekker, Inc.;
1996, 525-559.
5. Varney MD, Lester S, McCluskey J, Gao X, Tait BD. Match-
ing for HLA DPA1 and DPB1 alleles in unrelated bone marrow
transplantation. Hum Immunol. 1999;60:532-538.
6. Petersdorf EW, Gooley T, Malkki M, et al. The biological
signiﬁcance of HLA-DP gene variation in haematopoietic cell
transplantation. Br J Haematol. 2001;112:988-994.
7. Loiseau P, Espe´rou H, Busson M, et al. DPB1 disparities
contribute to severe GVHD and reduced patient survival after
unrelated donor bone marrow transplantation. Bone Marrow
Transplant. 2002;30:497-502.
8. Olerup O, Moller E, Persson U. HLA-DP incompatibilities
induce signiﬁcant proliferation in primary mixed lymphocyte
cultures in HLA-A, -B, -DR and -DQ compatible individuals:
implications for allogeneic bone marrow transplantation. Tissue
Antigens. 1990;36:194-202.
